Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND submission in Q1 2027

Novel Switch-II scaffold and pseudo-irreversible binding designed to enable prolonged, potent and selective inhibition of mutant KRAS to potentially achieve improved efficacy and tolerability

SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced the presentation of preclinical data on BH-501284 at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development, taking place September 25-28, 2026, in San Diego, CA. BH-501284 is a novel, orally bioavailable, non-covalent, pseudo-irreversible pan-KRAS inhibitor designed to overcome limitations of current KRAS-targeted therapies.